10-K · February 26, 2026
Intellia positions itself as a pioneer in in vivo CRISPR genome editing with two Phase 3 programs (lonvo-z for HAE and nex-z for ATTR). The company completed enrollment in the HAELO Phase 3 (80 patients) and plans…
Earnings analysis · 10-Q
NTLA earnings analysis
Filed May 11, 2026 · Our reading of the company's report
The latest report
Intellia Therapeutics reported Q1 2026 revenues of $15.0 million and a diluted EPS of -$0.81, exceeding analyst estimates. The company announced cash resources expected to fund operations at least into 2028, following a…
Read full summary
Intellia Therapeutics reported Q1 2026 revenues of $15.0 million and a diluted EPS of -$0.81, exceeding analyst estimates. The company announced cash resources expected to fund operations at least into 2028, following a successful public offering that raised approximately $207 million. Cost reductions were observed in R&D expenses, indicating a more sustainable operational approach moving forward.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.81
What stood out
-
Revenue Growth
Q1 2026 revenue reached $15.0 million, a positive change from $14 million in Q1 2025.
-
Improved EPS
Diluted EPS for Q1 2026 at -$0.81, improving from -$0.92 in Q1 2025.
-
Strong Cash Position
Cash, cash equivalents, and marketable securities amounted to $517.2 million as of March 31, 2026.
-
Cost Reductions
R&D expenses significantly decreased by $27.7 million (26%) from Q1 2025.
-
Successful Equity Offering
Raised $33.6 million in Q1 2026 through at-the-market offerings.
-
Regulatory Progress
Received RMAT designation for both nex-z and lonvo-z, expediting potential regulatory review.
What to watch
-
Negative Cash Flow
Operating cash flow was $117.3 million negative in Q1 2026, indicating ongoing cash burn.
-
Regulatory Approval Uncertainty
The company faces uncertainties regarding the approval of lonvo-z and nex-z due to the complex regulatory environment.
-
Competition Risks
Intense competition from other biotech firms targeting similar indications could impact market share.
Management's outlook
Outlook deferred to earnings press release / call.
Earlier filings 4
10-Q · August 7, 2025
Intellia reported Q2 2025 collaboration revenue of $14.245M, up from $6.957M in Q2 2024, and GAAP diluted loss per share improved to $(0.98) from $(1.52). Operating loss narrowed to $(109.996)M from $(139.043)M…
10-Q · November 7, 2024
Intellia reported collaboration revenue of $9.111M for Q3 2024 (down from $11.992M in Q3 2023) and a net loss of $135.712M (GAAP) or loss per share of $1.34 (improved from $1.38 a year ago). Operating loss widened to…
10-Q · August 8, 2024
Intellia reported Q2 collaboration revenue of $6.957M, down from $13.594M a year earlier and sharply below the prior quarter (~$28.935M). The company recorded an operating loss of $139.043M and GAAP net loss per share…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.